









## Active substances set

**Search phrase:** non-Hodgkin lymphoma

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### non-Hodgkin lymphoma

<b>Temsirolimus</b>	<p>Temsirolimus is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).</p>	<p> <b>NO REIMBURSEMENT</b></p> <p> <b>ESMO</b></p>
<b>Idelalisib</b>	<p>Idelalisib jest wskazany w monoterapii u dorosłych pacjentów z chłoniakiem grudkowym (ang. Follicular Lymphoma, FL), który jest oporny na dwie wcześniej zastosowane linie leczenia.</p>	<p> <b>NO REIMBURSEMENT</b></p> <p> <b>ESMO</b></p>
<b>Brentuximab vedotin</b>	<p>Brentuximab Vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory sALCL. Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.</p>	<p> <b>REIMBURSEMENT WITH RESTRICTIONS</b></p> <p> <b>ESMO</b></p>
<b>Ibrutinib</b>	<p>Ibrutinib as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).</p>	<p> <b>FULL REIMBURSEMENT</b></p> <p> <b>ESMO</b></p>

## **Obinutuzumab**

Obinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL.

Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

 **FULL REIMBURSEMENT**

 **ESMO**

---

## **Lenalidomide**

Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 - 3a).

Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

 **FULL REIMBURSEMENT**

 **ESMO**